Hepregen Raises $3 Million To Screen Drugs for Liver Damage

Luke Timmerman9/2/08

Hepregen, an MIT spinoff company developing a way to screen drugs in development for liver toxicity, has raised $3 million out of a $5 million first round of venture capital, according to a regulatory filing cited by Private Equity Hub. The backers of the company include Battelle Ventures and Innovation Valley Partners. Sangeeta Bhatia and Salman Khetani founded the company, according to this article in Technology Review.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.